Literature DB >> 35997692

Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022.

Kim Blom, Sebastian Havervall, Ulrika Marking, Nina Greilert Norin, Philip Bacchus, Ramona Groenheit, Andreas Bråve, Charlotte Thålin, Jonas Klingström.   

Abstract

Given the recent surge in SARS-CoV-2 Omicron infections, we performed a quantitative PCR screening survey during June 28-29, 2022, in Stockholm, Sweden, to investigate SARS-CoV-2 point prevalence in a group with high exposure risk. Results showed SARS-CoV-2 infection in 2.3% of healthcare workers who were asymptomatic at time of sampling.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Sweden; coronavirus disease; healthcare workers; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine-preventable diseases; viruses; zoonoses

Mesh:

Year:  2022        PMID: 35997692      PMCID: PMC9514358          DOI: 10.3201/eid2810.221093

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   16.126


Emerging data show a rapid increase in the prevalence of SARS-CoV-2 infection linked to an increase in COVID-19 cases, which is being driven by the SARS-CoV-2 Omicron variant. Compared with previous variants, Omicron has shown superior capacity for transmission and less sensitivity to neutralizing antibodies induced by vaccination or prior infection with other variants of the virus (). Initially, the Omicron sublineages BA.1 (including BA.1.1) and BA.2 spread globally at a rapid pace, infecting a large proportion of the population, including vaccinated persons. Nonetheless, vaccines have been shown to provide good protection against severe disease (). Recently, 2 new sublineages of Omicron, BA.4 and BA.5, have emerged (). These variants show an even stronger capacity to elude infection- and vaccine-induced immune responses, even evading antibodies in serum from BA.1-infected persons (,). Such findings raise concerns that a high community spread might lead to an increasing number of severe cases and a subsequent surge in global hospitalization rates. We performed a quantitative real-time PCR (qPCR) screening survey to estimate the point prevalence of SARS-CoV-2 infection among asymptomatic (defined as having no symptoms at time of sampling) healthcare workers at Danderyd Hospital, Stockholm, Sweden, during June 28–June 29, 2022. In April and May of 2020, the COMMUNITY study enrolled 2,149 healthcare workers employed at Danderyd Hospital (). Once enrolled, study participants provided blood samples every 4 months for SARS-CoV-2 serologic assessment (). Information regarding vaccination status was obtained through the Swedish vaccination register (VAL Vaccinera), and SARS-CoV-2 infection was determined by either seroconversion before vaccination or positive PCR test results obtained from the national communicable diseases register, SmiNet (Public Health Agency of Sweden). We conducted a qPCR screening survey during June 28–June 29, 2022. We invited all COMMUNITY-study participants who had provided a blood sample in January 2022 (n = 1,412) to participate in the screening survey via a mobile application program. We restricted participation in the survey to healthcare workers who were actively working and who had been asymptomatic for >5 days before screening. We gathered self-administered naso-oropharyngeal/saliva swab specimens (), which were collected at Danderyd Hospital during work hours, and transported those samples to the National Pandemic Center in Stockholm for assessment by qPCR. The screening survey was approved by the Swedish Ethical Review Authority (dnr 2020–01653) and conducted in accordance with the declaration of Helsinki. We obtained written informed consent from all survey participants. A total of 259 healthcare workers (18.3% of all invited participants) with no symptoms at the time of inclusion underwent qPCR screening. A large proportion (88%) of participants had received 3 vaccine doses, and 50% had been confirmed as having 1 (46%) or 2 (4%) prior SARS-CoV-2 infection(s) (Table). In total, 6 participants (2.3% [95% CI 1.1%–5.0%]) tested positive by qPCR screening; 5 had received 3 vaccine doses, and 2 had a confirmed previous SARS-CoV-2 infection (Table). Just 1 of the 6 participants who tested positive was unvaccinated and previously uninfected. Five samples could be successfully sequenced, revealing 1 infection traced to the BA.2.9.2 sublineage and 4 infections traced to BA.5 (BA.5.1 [2 cases], BA.5.2, and BA.5.3), suggesting community spread of several variants of Omicron. Isolation on A549-ACE2 cells was successfully accomplished for 2 samples.
Table

Characteristics of 259 asymptomatic HCWs who participated in a quantitative real-time PCR screening survey, Stockholm, Sweden, June 28–29, 2022*

CharacteristicAll HCWs
Infected HCWs
Total
259 (100)
6 (2.3)
Sex
M26 (60)1 (17)
F
233 (40)
5 (83)
Median age, y
51
48
Vaccination status
No vaccination5 (2)1 (17)
1 vaccine dose2 (1)0
2 vaccine doses24 (9)0
3 vaccine doses
228 (88)
5 (83)
Previous Infections
1 infection119 (46)2 (33)
2 infections
11 (4)0

*Values are no. (%) except as indicated. HCW, healthcare worker.

*Values are no. (%) except as indicated. HCW, healthcare worker. A 2.3% point prevalence of SARS-CoV-2 infection among asymptomatic healthcare workers indicates widespread transmission of SARS-CoV-2. This prevalence aligns with estimates from the United Kingdom (), where ≈1 in 30 persons was estimated to be infected by SARS-CoV-2 on July 1, 2022. A recent survey conducted in March 2022 during the BA.1/BA.2 wave estimated an overall prevalence of SARS-CoV-2 infection in Sweden of 1.4% (). Although our survey differs in design from that earlier survey, results of both indicate a trend of increased circulation of variants in the population of Sweden, despite the summer season, high vaccine coverage, and a high rate of prior infection. Additional PCR screenings of our cohort, conducted before the survey we report, revealed that ≈10% of SARS-CoV-2-infected participants remained asymptomatic over the course of the infection (). In parallel with the testing on June 28–29, we performed a substudy using the same cohort during the same days to attempt to isolate the BA.5 sublineage from participants diagnosed with COVID-19 within the previous 5 days. Ten participants were included, and the BA.5 variant of the virus could be isolated on A549-ACE2 cells in 5 samples. Ten people is likely an underrepresentation of true cases in this cohort, but these findings show nonetheless that at least 0.7% of the healthcare workers were diagnosed with COVID-19 at the same time as an additional 2.3% of the healthcare workers had an asymptomatic infection. We theorize that the latest surge in SARS-CoV-2 infection, in Sweden and elsewhere, can be likely explained by the emergence of the BA.5 variant. The observed prevalence of 2.3% in asymptomatic healthcare workers in Sweden implies a need to take precautions to protect this high-risk population, in hospitals and all other vulnerable settings.
  8 in total

1.  Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Authors:  Aekkachai Tuekprakhon; Rungtiwa Nutalai; Aiste Dijokaite-Guraliuc; Daming Zhou; Helen M Ginn; Muneeswaran Selvaraj; Chang Liu; Alexander J Mentzer; Piyada Supasa; Helen M E Duyvesteyn; Raksha Das; Donal Skelly; Thomas G Ritter; Ali Amini; Sagida Bibi; Sandra Adele; Sile Ann Johnson; Bede Constantinides; Hermione Webster; Nigel Temperton; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Derrick Crook; Andrew J Pollard; Teresa Lambe; Philip Goulder; Neil G Paterson; Mark A Williams; David R Hall; Elizabeth E Fry; Jiandong Huo; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton
Journal:  Cell       Date:  2022-06-09       Impact factor: 66.850

2.  Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.

Authors:  Kim Blom; Ulrika Marking; Sebastian Havervall; Nina Greilert Norin; Max Gordon; Marina García; Teghesti Tecleab; Wanda Christ; Mattias Forsell; Mia Phillipson; Peter Nilsson; Sara Mangsbo; Sophia Hober; Mikael Åberg; Jonas Klingström; Charlotte Thålin
Journal:  Lancet Infect Dis       Date:  2022-06-09       Impact factor: 71.421

3.  SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.

Authors:  Ann-Sofie Rudberg; Sebastian Havervall; Anna Månberg; August Jernbom Falk; Katherina Aguilera; Henry Ng; Lena Gabrielsson; Ann-Christin Salomonsson; Leo Hanke; Ben Murrell; Gerald McInerney; Jennie Olofsson; Eni Andersson; Cecilia Hellström; Shaghayegh Bayati; Sofia Bergström; Elisa Pin; Ronald Sjöberg; Hanna Tegel; My Hedhammar; Mia Phillipson; Peter Nilsson; Sophia Hober; Charlotte Thålin
Journal:  Nat Commun       Date:  2020-10-08       Impact factor: 14.919

4.  Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.

Authors:  Sebastian Havervall; Ulrika Marking; Nina Greilert-Norin; Max Gordon; Henry Ng; Wanda Christ; Mia Phillipson; Peter Nilsson; Sophia Hober; Kim Blom; Jonas Klingström; Sara Mangsbo; Mikael Åberg; Charlotte Thålin
Journal:  Clin Transl Immunology       Date:  2022-04-18

5.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.

Authors:  Heba N Altarawneh; Hiam Chemaitelly; Houssein H Ayoub; Patrick Tang; Mohammad R Hasan; Hadi M Yassine; Hebah A Al-Khatib; Maria K Smatti; Peter Coyle; Zaina Al-Kanaani; Einas Al-Kuwari; Andrew Jeremijenko; Anvar H Kaleeckal; Ali N Latif; Riyazuddin M Shaik; Hanan F Abdul-Rahim; Gheyath K Nasrallah; Mohamed G Al-Kuwari; Adeel A Butt; Hamad E Al-Romaihi; Mohamed H Al-Thani; Abdullatif Al-Khal; Roberto Bertollini; Laith J Abu-Raddad
Journal:  N Engl J Med       Date:  2022-06-15       Impact factor: 176.079

6.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.

Authors:  Yunlong Cao; Ayijiang Yisimayi; Fanchong Jian; Weiliang Song; Tianhe Xiao; Lei Wang; Shuo Du; Jing Wang; Qianqian Li; Xiaosu Chen; Yuanling Yu; Peng Wang; Zhiying Zhang; Pulan Liu; Ran An; Xiaohua Hao; Yao Wang; Jing Wang; Rui Feng; Haiyan Sun; Lijuan Zhao; Wen Zhang; Dong Zhao; Jiang Zheng; Lingling Yu; Can Li; Na Zhang; Rui Wang; Xiao Niu; Sijie Yang; Xuetao Song; Yangyang Chai; Ye Hu; Yansong Shi; Linlin Zheng; Zhiqiang Li; Qingqing Gu; Fei Shao; Weijin Huang; Ronghua Jin; Zhongyang Shen; Youchun Wang; Xiangxi Wang; Junyu Xiao; Xiaoliang Sunney Xie
Journal:  Nature       Date:  2022-06-17       Impact factor: 69.504

7.  Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.

Authors:  Houriiyah Tegally; Monika Moir; Josie Everatt; Marta Giovanetti; Cathrine Scheepers; Eduan Wilkinson; Kathleen Subramoney; Zinhle Makatini; Sikhulile Moyo; Daniel G Amoako; Cheryl Baxter; Christian L Althaus; Ugochukwu J Anyaneji; Dikeledi Kekana; Raquel Viana; Jennifer Giandhari; Richard J Lessells; Tongai Maponga; Dorcas Maruapula; Wonderful Choga; Mogomotsi Matshaba; Mpaphi B Mbulawa; Nokukhanya Msomi; Yeshnee Naidoo; Sureshnee Pillay; Tomasz Janusz Sanko; James E San; Lesley Scott; Lavanya Singh; Nonkululeko A Magini; Pamela Smith-Lawrence; Wendy Stevens; Graeme Dor; Derek Tshiabuila; Nicole Wolter; Wolfgang Preiser; Florette K Treurnicht; Marietjie Venter; Georginah Chiloane; Caitlyn McIntyre; Aine O'Toole; Christopher Ruis; Thomas P Peacock; Cornelius Roemer; Sergei L Kosakovsky Pond; Carolyn Williamson; Oliver G Pybus; Jinal N Bhiman; Allison Glass; Darren P Martin; Ben Jackson; Andrew Rambaut; Oluwakemi Laguda-Akingba; Simani Gaseitsiwe; Anne von Gottberg; Tulio de Oliveira
Journal:  Nat Med       Date:  2022-06-27       Impact factor: 87.241

8.  Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Authors:  Wanwisa Dejnirattisai; Robert H Shaw; Piyada Supasa; Chang Liu; Arabella Sv Stuart; Andrew J Pollard; Xinxue Liu; Teresa Lambe; Derrick Crook; Dave I Stuart; Juthathip Mongkolsapaya; Jonathan S Nguyen-Van-Tam; Matthew D Snape; Gavin R Screaton
Journal:  Lancet       Date:  2021-12-20       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.